



Atty.  
Dkt. No.

M#

Client Ref.

037003

0280617

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: NABIL HANNA et al.

Appln. No.: 09/853,581

Filing Date: May 14, 2001

Date: September 24, 2004

Page

1

of

1

Examiner: Gary B. Nickol

Group Art Unit: 1642

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
GN	AR 5,585,103	12/17/96	Raychaudhuri, et al. (claims only)			7/24/92
	BR 5,695,770	12/9/97	Raychaudhuri, et al. (claims only)			6/7/95
	CR 5,709,860	1/20/98	Raychaudhuri, et al. (claims only)			12/7/94
	DR 6,197,311	3/6/01	Raychaudhuri, et al. (claims only)			2/17/98
	ER					
	FR					
	GR					
	HR					
	IR					
	JR					
	KR					
	LR					
	MR					
	NR					

## FOREIGN PATENT DOCUMENTS

ENGLISH ABSTRACT DOCUMENT						Abstract		Readily Available		
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	OR									
	PR									
	QR									
	RR									
	SR									
	TR									
	UR									
	VR									
	WR									
	XR									

## OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

GN	YR	Francis R. Carbone and Michael J. Bevan, "Class I-Restricted Processing and Presentation of Exogenous Cell-Associated with Antigen In Vivo," February 1990, 171:377-387.				
GN	ZR	Hidemi Takahashi, Toshiyuki Takeshita, Bror Morein, Scott Putney, Ronald N. Germain and Jay A. Berzofsky, "Induction of CD8 <sup>+</sup> Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs" <i>Nature</i> , April 26, 1990, 344:873-875				
GN	AAI	Mark W. Moore, Francis R. Carbone, and Michael J. Bevan, "Introduction of Soluble Protein into the Class I Pathway of Antigen Processing and Presentation" <i>Cell</i> , September 9, 1988, 54:777-785				

GW	BBF	Brown et al., Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol. 2004 Jun;125(6):743-8. <i>Abstract only</i>				
GW	CCF	Comerci et al., Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer. 1996 Mar 15;77(6):1107-14. <i>Abstract only</i>				
GW	DDF	De Wever et al., Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF- $\beta$ or wounding. J Cell Sci. 2004 Oct 15;117(Pt 20):4691-4703. Epub 2004 Aug 25. <i>Abstract only</i>				
GW	EEF	Hasegawa et al., Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001 Mar 1;91(5):964-71. <i>Abstract only</i>				
GW	FFF	Lee et al., Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int J Cancer. 2001 Nov 15;94(4):500-7. <i>Abstract</i>				
GW	GGF	Matsunaga et al., Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta. Ann Hematol. 2004 May;83(5):322-5. Epub 2003 Nov 11. <i>Abstract only</i>				
GW	HHF	Medrano et al., Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene. 2003 May 19;22(20):3123-9. <i>Abstract only</i>				
GW	IIR	Mitani, Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. 2004 May 24;23(24):4263-9. <i>Abstract only</i>				
GW	JJR	Mitropoulos et al., Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res. 2004 Sep 7 [Epub ahead of print] <i>Abstract only</i>				
GW	KKF	Matar et al., Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol. 2001 Feb;1(2):307-19. <i>Abstract only</i>				
GW	LLR	Piestrzeniewicz-Ulanska et al., Expression and intracellular localization of Smad proteins in human endometrial cancer. Oncol Rep. 2003 Sep-Oct;10(5):1539-44. <i>Abstract only</i>				
GW	MMF	Sacco et al., Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine. 2000 Jun;12(6):811-4. <i>Abstract only</i>				
GW	NNF	Schiemann et al. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev. 2004;28(1):57-64. <i>Abstract only</i>				
GW	OOF	Seoane et al., Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004 Apr 16;117(2):211-23. <i>Abstract only</i>				
GW	PPF	Shariat et al., Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 1;19(11):2856-64. <i>Abstract only</i>				
GW	QQF	Shariat et al., Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15;92(12):2985-92. <i>Abstract only</i>				
GW	RRF	Sheen-Chen et al., Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg. 2001 Aug;136(8):937-40. <i>Abstract</i>				

GN	SSR	Subramanian et al. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res. 2004 Aug 1;64(15):5200-11. <i>Abstract only</i>				
GN	TTR	Lian et al., Enhanced expression of transforming growth factor-beta isoforms in the neural tube of embryos derived from diabetic mice exposed to cyclophosphamide. Neurosci Lett. 2003 Nov 6;351(1):51-5. <i>Abstract</i>				
GN	UUP	Weiner et al., Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler. 2002 Apr;8(2):142-54. <i>Abstract only</i>				
GN	VVF	Xu et al., Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer. 1999 Aug 20;84(4):396-9. <i>Abstract only</i>				
GN	WW	Xi et al., Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer. J Huazhong Univ Sci Technolog Med Sci. 2004;24(1):62-5. <i>Abstract only</i>				
GN	XXR	Xiong et al., Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. World J Gastroenterol. 2002 Aug;8(4):674-8. <i>Abstract</i>				
GN	YYR	Takiguchi et al., Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor. Anticancer Res. 2004, 24(3a):1823-8. <i>Abstract only</i>				

Examiner

*Jany B. Nickel*

Date Considered:

*12/10/04*

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.